Feb 24 (Reuters) - AVITA Medical Inc RCEL.O :
- EXPECT FDA APPROVAL FOR SOFT TISSUE REPAIR INDICATION IN JUNE 2023 FOLLOWED BY COMMERCIAL LAUNCH ON JULY 1, 2023
- EXPECT FDA APPROVAL FOR VITILIGO INDICATION IN JUNE 2023
- COMMERCIAL REVENUE, WHICH EXCLUDES BARDA REVENUE, FOR Q1 2023 IS EXPECTED TO BE IN RANGE OF $10 TO $11 MILLION
- COMMERCIAL REVENUE, WHICH EXCLUDES BARDA REVENUE, FOR FULL YEAR 2023 IS EXPECTED TO BE IN RANGE OF $49 TO $51 MILLION
News: AVH Avita Medical Expects FDA Approval For Soft Tissue Repair Indication In June 2023
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.34 |
Change
0.065(5.10%) |
Mkt cap ! $98.69M | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.35 | $1.29 | $484.3K | 367.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6881 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.34 | 623 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2025 (20 minute delay) ? |
| AVH (ASX) Chart |